Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support

L. S. Schwartzberg, C. H. Weaver, R. Birch, R. Giudice, E. Sobong, F. Schnell, L. Kalman, C. D. Buckner

Research output: Contribution to journalArticle

Abstract

The purpose of this trial was to determine the effects of paclitaxel in patients with newly diagnosed metastatic breast cancer scheduled to receive high-dose chemotherapy with peripheral blood stem cell support. Eighty-four patients received anthracycline-based induction and two doses of paclitaxel at 170 mg/m2 (n = 52) or 250 mg/m2 (n = 32). Eighty-two (98%) received cyclophosphamide and etoposide (n = 50) or paclitaxel and cyclophosphamide (n = 32) with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells, and 79 (94%) received cyclophosphamide, thiotepa, and carboplatin with peripheral blood stem cell support. One patient (1%) died of infection and 56 (67%) died of progressive disease. For patients with measurable disease, the complete response rate was 21% after induction and 29% after paclitaxel (p = 0.54). Results were compared with those of 125 patients who received the same sequence of therapy without paclitaxel. The complete response rate after high-dose chemotherapy was 54% for patients receiving paclitaxel and 62% for those not receiving paclitaxel (p = 0.60). The probabilities of overall survival and event-free survival at 3 years for patients receiving paclitaxel were 46% and 24%, respectively, compared with 54% and 22%, respectively, for patients not receiving paclitaxel (p = 0.62). Further trials evaluating this dose and schedule of paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy are not warranted.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number2
DOIs
StatePublished - Apr 1 1999

Fingerprint

Paclitaxel
Breast Neoplasms
Drug Therapy
Cyclophosphamide
Peripheral Blood Stem Cells
Thiotepa
Anthracyclines
Carboplatin
Granulocyte Colony-Stimulating Factor
Etoposide
Disease-Free Survival
Appointments and Schedules
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support. / Schwartzberg, L. S.; Weaver, C. H.; Birch, R.; Giudice, R.; Sobong, E.; Schnell, F.; Kalman, L.; Buckner, C. D.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, No. 2, 01.04.1999, p. 162-167.

Research output: Contribution to journalArticle

@article{a84f2c815fef4059b0f15e045da83208,
title = "Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support",
abstract = "The purpose of this trial was to determine the effects of paclitaxel in patients with newly diagnosed metastatic breast cancer scheduled to receive high-dose chemotherapy with peripheral blood stem cell support. Eighty-four patients received anthracycline-based induction and two doses of paclitaxel at 170 mg/m2 (n = 52) or 250 mg/m2 (n = 32). Eighty-two (98{\%}) received cyclophosphamide and etoposide (n = 50) or paclitaxel and cyclophosphamide (n = 32) with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells, and 79 (94{\%}) received cyclophosphamide, thiotepa, and carboplatin with peripheral blood stem cell support. One patient (1{\%}) died of infection and 56 (67{\%}) died of progressive disease. For patients with measurable disease, the complete response rate was 21{\%} after induction and 29{\%} after paclitaxel (p = 0.54). Results were compared with those of 125 patients who received the same sequence of therapy without paclitaxel. The complete response rate after high-dose chemotherapy was 54{\%} for patients receiving paclitaxel and 62{\%} for those not receiving paclitaxel (p = 0.60). The probabilities of overall survival and event-free survival at 3 years for patients receiving paclitaxel were 46{\%} and 24{\%}, respectively, compared with 54{\%} and 22{\%}, respectively, for patients not receiving paclitaxel (p = 0.62). Further trials evaluating this dose and schedule of paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy are not warranted.",
author = "Schwartzberg, {L. S.} and Weaver, {C. H.} and R. Birch and R. Giudice and E. Sobong and F. Schnell and L. Kalman and Buckner, {C. D.}",
year = "1999",
month = "4",
day = "1",
doi = "10.1097/00000421-199904000-00011",
language = "English (US)",
volume = "22",
pages = "162--167",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support

AU - Schwartzberg, L. S.

AU - Weaver, C. H.

AU - Birch, R.

AU - Giudice, R.

AU - Sobong, E.

AU - Schnell, F.

AU - Kalman, L.

AU - Buckner, C. D.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - The purpose of this trial was to determine the effects of paclitaxel in patients with newly diagnosed metastatic breast cancer scheduled to receive high-dose chemotherapy with peripheral blood stem cell support. Eighty-four patients received anthracycline-based induction and two doses of paclitaxel at 170 mg/m2 (n = 52) or 250 mg/m2 (n = 32). Eighty-two (98%) received cyclophosphamide and etoposide (n = 50) or paclitaxel and cyclophosphamide (n = 32) with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells, and 79 (94%) received cyclophosphamide, thiotepa, and carboplatin with peripheral blood stem cell support. One patient (1%) died of infection and 56 (67%) died of progressive disease. For patients with measurable disease, the complete response rate was 21% after induction and 29% after paclitaxel (p = 0.54). Results were compared with those of 125 patients who received the same sequence of therapy without paclitaxel. The complete response rate after high-dose chemotherapy was 54% for patients receiving paclitaxel and 62% for those not receiving paclitaxel (p = 0.60). The probabilities of overall survival and event-free survival at 3 years for patients receiving paclitaxel were 46% and 24%, respectively, compared with 54% and 22%, respectively, for patients not receiving paclitaxel (p = 0.62). Further trials evaluating this dose and schedule of paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy are not warranted.

AB - The purpose of this trial was to determine the effects of paclitaxel in patients with newly diagnosed metastatic breast cancer scheduled to receive high-dose chemotherapy with peripheral blood stem cell support. Eighty-four patients received anthracycline-based induction and two doses of paclitaxel at 170 mg/m2 (n = 52) or 250 mg/m2 (n = 32). Eighty-two (98%) received cyclophosphamide and etoposide (n = 50) or paclitaxel and cyclophosphamide (n = 32) with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells, and 79 (94%) received cyclophosphamide, thiotepa, and carboplatin with peripheral blood stem cell support. One patient (1%) died of infection and 56 (67%) died of progressive disease. For patients with measurable disease, the complete response rate was 21% after induction and 29% after paclitaxel (p = 0.54). Results were compared with those of 125 patients who received the same sequence of therapy without paclitaxel. The complete response rate after high-dose chemotherapy was 54% for patients receiving paclitaxel and 62% for those not receiving paclitaxel (p = 0.60). The probabilities of overall survival and event-free survival at 3 years for patients receiving paclitaxel were 46% and 24%, respectively, compared with 54% and 22%, respectively, for patients not receiving paclitaxel (p = 0.62). Further trials evaluating this dose and schedule of paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy are not warranted.

UR - http://www.scopus.com/inward/record.url?scp=0033495947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033495947&partnerID=8YFLogxK

U2 - 10.1097/00000421-199904000-00011

DO - 10.1097/00000421-199904000-00011

M3 - Article

C2 - 10199451

AN - SCOPUS:0033495947

VL - 22

SP - 162

EP - 167

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -